Tonix Pharmaceuticals Initiates Enrollment In MGH Phase 2 'STROBE' Study of TNX-1900 (Intranasal Potentiated Oxytocin) For Binge-Eating Disorder
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals has initiated enrollment in the Massachusetts General Hospital (MGH) Phase 2 'STROBE' study of TNX-1900, an intranasal potentiated oxytocin, for the treatment of binge-eating disorder.
July 31, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals' initiation of Phase 2 study enrollment for TNX-1900 could potentially lead to positive outcomes for the company if the study yields successful results.
The initiation of Phase 2 study enrollment for TNX-1900 indicates progress in Tonix Pharmaceuticals' product pipeline. If the study yields successful results, it could potentially lead to FDA approval and commercialization of the drug, which would positively impact the company's revenues and, consequently, its stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100